Epirizole

Identification

Name
Epirizole
Accession Number
DB08991
Type
Small Molecule
Groups
Approved
Description

Epirizole is a nonsteroidal anti-inflammatory drug (NSAID).

Structure
Thumb
Synonyms
  • 4-methoxy-2-(5-methoxy-3-methylpyrazol-1-yl)-6-methylpyrimidine
  • Epirizole
  • Mebron
  • Methopyrimazole
  • Polihexanid
External IDs
DA 398 / DA-398 / Knoll 533
Product Ingredients
IngredientUNIICASInChI Key
Epirizole hydrochloride138HY1BQ0TNot AvailableYJVOCLSBUGKSCI-UHFFFAOYSA-N
International/Other Brands
Karmarte (Toho) / Mebron (Daiichi Sankyo)
Categories
UNII
3B46O2FH8I
CAS number
18694-40-1
Weight
Average: 234.2545
Monoisotopic: 234.111675712
Chemical Formula
C11H14N4O2
InChI Key
RHAXSHUQNIEUEY-UHFFFAOYSA-N
InChI
InChI=1S/C11H14N4O2/c1-7-5-9(16-3)13-11(12-7)15-10(17-4)6-8(2)14-15/h5-6H,1-4H3
IUPAC Name
4-methoxy-2-(5-methoxy-3-methyl-1H-pyrazol-1-yl)-6-methylpyrimidine
SMILES
COC1=CC(C)=NN1C1=NC(C)=CC(OC)=N1

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Epirizole.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Epirizole is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Epirizole is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Epirizole is combined with 5-androstenedione.Experimental, Illicit
AbciximabEpirizole may increase the anticoagulant activities of Abciximab.Approved
AcebutololEpirizole may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Epirizole.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Epirizole is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolEpirizole may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Epirizole.Approved, Vet Approved
AclarubicinEpirizole may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Epirizole.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Epirizole is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Epirizole is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Epirizole is combined with Aldosterone.Experimental, Investigational
AldoxorubicinEpirizole may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level.Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Epirizole is combined with Alendronic acid.Approved
AliskirenEpirizole may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Epirizole is combined with Alminoprofen.Experimental
AlprenololEpirizole may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Epirizole.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Epirizole is combined with Amcinonide.Approved
AmikacinEpirizole may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Investigational, Vet Approved
AmilorideEpirizole may decrease the antihypertensive activities of Amiloride.Approved
AmrubicinEpirizole may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodEpirizole may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Epirizole.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Epirizole is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Epirizole is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Epirizole is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Epirizole is combined with Anisodamine.Investigational
AnnamycinEpirizole may decrease the excretion rate of Annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Epirizole.Approved, Investigational
Antithrombin III humanEpirizole may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanEpirizole may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Epirizole is combined with Apocynin.Investigational
ApramycinEpirizole may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Epirizole.Approved, Investigational
ArbekacinEpirizole may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinEpirizole may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanEpirizole may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololEpirizole may decrease the antihypertensive activities of Arotinolol.Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Epirizole is combined with Atamestane.Investigational
AtenololEpirizole may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Epirizole.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Epirizole.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Epirizole is combined with Azficel-T.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Epirizole.Approved, Investigational
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Epirizole.Investigational
BalsalazideEpirizole may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BecaplerminEpirizole may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Epirizole is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololEpirizole may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinEpirizole may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Epirizole is combined with Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Epirizole is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Epirizole.Approved
BenorilateThe risk or severity of adverse effects can be increased when Epirizole is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Epirizole.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Epirizole is combined with Benzydamine.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Epirizole.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Epirizole is combined with Betamethasone.Approved, Vet Approved
BetaxololEpirizole may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Epirizole.Approved, Investigational
BevantololEpirizole may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Epirizole is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Epirizole.Approved, Investigational
BisoprololEpirizole may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinEpirizole may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololEpirizole may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Epirizole.Approved
BucillamineThe risk or severity of adverse effects can be increased when Epirizole is combined with Bucillamine.Investigational
BucindololEpirizole may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Epirizole is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Epirizole is combined with Bufexamac.Approved, Experimental
BufuralolEpirizole may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Epirizole is combined with Bumadizone.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Epirizole.Approved
BupranololEpirizole may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Epirizole.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Epirizole.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Epirizole is combined with Candoxatril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Epirizole is combined with Captopril.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Epirizole is combined with Carbaspirin calcium.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Epirizole.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Epirizole.Approved, Vet Approved, Withdrawn
CarteololEpirizole may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolEpirizole may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Epirizole.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Epirizole is combined with Celecoxib.Approved, Investigational
CeliprololEpirizole may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinEpirizole may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Epirizole.Approved, Investigational, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Epirizole.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Epirizole.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Epirizole resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Epirizole.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Epirizole is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Epirizole is combined with Cilazapril.Approved
CinoxacinEpirizole may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
Citric AcidEpirizole may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Epirizole is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Epirizole is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Epirizole is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Epirizole is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Epirizole is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Epirizole is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Epirizole.Vet Approved
CloranololEpirizole may decrease the antihypertensive activities of Cloranolol.Experimental
ColesevelamColesevelam can cause a decrease in the absorption of Epirizole resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Epirizole resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Epirizole is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Epirizole is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Epirizole is combined with Cortisone acetate.Approved, Investigational
CurcuminThe risk or severity of adverse effects can be increased when Epirizole is combined with Curcumin.Approved, Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Epirizole.Experimental
CyclosporineEpirizole may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateEpirizole may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinEpirizole may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidEpirizole may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanEpirizole may increase the anticoagulant activities of Darexaban.Investigational
DaunorubicinEpirizole may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Epirizole is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Epirizole is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Epirizole is combined with Delapril.Experimental
DesirudinEpirizole may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Epirizole is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Epirizole is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Epirizole is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Epirizole is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Epirizole is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Epirizole is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Epirizole is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Epirizole.Approved, Investigational
DextranEpirizole may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
Dextran 40Epirizole may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Epirizole may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Epirizole may increase the anticoagulant activities of Dextran 75.Approved
DibekacinEpirizole may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
Dibotermin alfaThe risk or severity of adverse effects can be increased when Epirizole is combined with Dibotermin alfa.Approved, Investigational
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Epirizole.Approved, Vet Approved
DicoumarolEpirizole may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Epirizole is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Epirizole is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Epirizole.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Epirizole is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Epirizole is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Epirizole.Approved
DihydrostreptomycinEpirizole may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Epirizole.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Epirizole.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Epirizole.Approved
DoxorubicinEpirizole may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneEpirizole may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Epirizole is combined with Droxicam.Withdrawn
DuvelisibThe risk or severity of adverse effects can be increased when Epirizole is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Epirizole is combined with E-6201.Investigational
Edetic AcidEpirizole may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanEpirizole may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Epirizole is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Epirizole is combined with Enalaprilat.Approved
EnoxacinEpirizole may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinEpirizole may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Epirizole.Experimental
EpanololEpirizole may decrease the antihypertensive activities of Epanolol.Experimental
EpirubicinEpirizole may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Epirizole.Experimental
EplerenoneEpirizole may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Epirizole.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Epirizole.Approved
EquileninThe risk or severity of adverse effects can be increased when Epirizole is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Epirizole is combined with Equilin.Approved
EsmololEpirizole may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Epirizole is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Epirizole is combined with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Epirizole.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Epirizole.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Epirizole is combined with Ethenzamide.Experimental
Ethyl biscoumacetateEpirizole may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Epirizole is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Epirizole is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Epirizole.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Epirizole is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Epirizole is combined with Evening primrose oil.Approved, Investigational
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Epirizole.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Epirizole.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Epirizole.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Epirizole.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Epirizole.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Epirizole is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Epirizole is combined with Feprazone.Experimental
Ferulic acidEpirizole may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Epirizole.Approved, Investigational
FleroxacinEpirizole may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Epirizole.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Epirizole is combined with Fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Epirizole is combined with Fludrocortisone.Approved, Investigational
FluindioneEpirizole may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumequineEpirizole may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Epirizole is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Epirizole is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Epirizole is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Epirizole is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Epirizole is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Epirizole is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Epirizole is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Epirizole is combined with Fluorometholone.Approved, Investigational
FluprednideneThe risk or severity of adverse effects can be increased when Epirizole is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Epirizole is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Epirizole.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Epirizole is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Epirizole.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Epirizole is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Epirizole is combined with Fluticasone propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Epirizole.Approved, Nutraceutical, Vet Approved
FondaparinuxEpirizole may increase the anticoagulant activities of Fondaparinux.Approved, Investigational
Fondaparinux sodiumEpirizole may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Epirizole.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Epirizole is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Epirizole is combined with Fosinopril.Approved
FramycetinEpirizole may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Epirizole.Approved, Vet Approved
GabexateEpirizole may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinEpirizole may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinEpirizole may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Epirizole.Approved, Withdrawn
GemifloxacinEpirizole may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinEpirizole may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinEpirizole may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AEpirizole may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GPX-150Epirizole may decrease the excretion rate of GPX-150 which could result in a higher serum level.Investigational
GrepafloxacinEpirizole may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Epirizole is combined with Guacetisal.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Epirizole is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Epirizole is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Epirizole is combined with HE3286.Investigational
HeparinEpirizole may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Epirizole is combined with Higenamine.Investigational
HydralazineEpirizole may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Epirizole.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Epirizole is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Epirizole.Approved, Investigational
Hygromycin BEpirizole may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Epirizole is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Epirizole.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Epirizole.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Epirizole.Approved, Investigational
IdarubicinEpirizole may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdraparinuxEpirizole may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Epirizole.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Epirizole is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Epirizole is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Epirizole.Approved
IndenololEpirizole may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Epirizole is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Epirizole.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Epirizole.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Epirizole.Approved, Investigational
IsepamicinEpirizole may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Epirizole.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Epirizole is combined with Istaroxime.Investigational
KanamycinEpirizole may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Epirizole.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Epirizole.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Epirizole.Approved
LabetalolEpirizole may decrease the antihypertensive activities of Labetalol.Approved
LandiololEpirizole may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Epirizole.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Epirizole.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Epirizole.Approved, Investigational
LepirudinEpirizole may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanEpirizole may increase the anticoagulant activities of Letaxaban.Investigational
LevobunololEpirizole may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinEpirizole may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Epirizole.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Epirizole is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Epirizole is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Epirizole.Approved
LonazolacThe risk or severity of adverse effects can be increased when Epirizole is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Epirizole.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Epirizole.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Epirizole is combined with Loteprednol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Epirizole is combined with Loxoprofen.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Epirizole.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Epirizole is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Epirizole.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Epirizole.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Epirizole.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Epirizole is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Epirizole.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Epirizole is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Epirizole.Approved
MelagatranEpirizole may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Epirizole is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Epirizole.Approved, Vet Approved
MepindololEpirizole may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineEpirizole may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Epirizole.Approved, Investigational, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Epirizole.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Epirizole.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Epirizole is combined with Methylprednisolone.Approved, Vet Approved
MetipranololEpirizole may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Epirizole.Approved
MetoprololEpirizole may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideEpirizole may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MicronomicinEpirizole may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Epirizole.Approved, Experimental
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Epirizole.Approved
MizoribineThe risk or severity of adverse effects can be increased when Epirizole is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Epirizole is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Epirizole is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Epirizole is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Epirizole.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Epirizole.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Epirizole.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Epirizole is combined with Nabumetone.Approved
NadololEpirizole may decrease the antihypertensive activities of Nadolol.Approved
NadroparinEpirizole may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatEpirizole may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Epirizole.Approved
Nalidixic AcidEpirizole may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Epirizole.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Epirizole is combined with NCX 1022.Investigational
NeamineEpirizole may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololEpirizole may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NemonoxacinEpirizole may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinEpirizole may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Epirizole.Approved, Investigational
NetilmicinEpirizole may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Epirizole is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Epirizole.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Epirizole.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Epirizole is combined with Nitroaspirin.Investigational
NorfloxacinEpirizole may increase the neuroexcitatory activities of Norfloxacin.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Epirizole is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Epirizole.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Epirizole.Approved
OlsalazineEpirizole may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Epirizole is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatThe risk or severity of adverse effects can be increased when Epirizole is combined with Omapatrilat.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Epirizole is combined with Orgotein.Vet Approved
OtamixabanEpirizole may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Epirizole.Approved
Oxolinic acidEpirizole may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololEpirizole may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Epirizole.Approved, Withdrawn
PamidronateThe risk or severity of adverse effects can be increased when Epirizole is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Epirizole is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Epirizole is combined with Parecoxib.Approved
ParomomycinEpirizole may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Epirizole is combined with Parthenolide.Approved, Investigational
PazufloxacinEpirizole may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinEpirizole may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololEpirizole may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateEpirizole may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateEpirizole may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Epirizole is combined with Perindopril.Approved
PhenindioneEpirizole may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonEpirizole may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Epirizole.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Epirizole.Approved, Investigational
PindololEpirizole may decrease the antihypertensive activities of Pindolol.Approved, Investigational
Pipemidic acidEpirizole may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PirarubicinEpirizole may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Epirizole.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Epirizole.Approved, Investigational
Piromidic acidEpirizole may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Epirizole.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Epirizole is combined with Pirprofen.Experimental
PitolisantThe risk or severity of adverse effects can be increased when Epirizole is combined with Pitolisant.Approved, Investigational
Platelet Activating FactorEpirizole may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinEpirizole may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PlicamycinEpirizole may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Investigational, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Epirizole.Approved
PractololEpirizole may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Epirizole.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Epirizole is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Epirizole is combined with Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Epirizole is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Epirizole is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Epirizole is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Epirizole is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Epirizole is combined with Pregnenolone.Approved, Experimental, Investigational
ProbenecidThe serum concentration of Epirizole can be increased when it is combined with Probenecid.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Epirizole is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Epirizole is combined with Propacetamol.Approved, Investigational
PropranololEpirizole may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Epirizole is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Epirizole is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Epirizole.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Epirizole.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Epirizole.Vet Approved
Protein CEpirizole may increase the anticoagulant activities of Protein C.Approved
Protein S humanEpirizole may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeEpirizole may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinEpirizole may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Epirizole.Investigational
PuromycinEpirizole may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Epirizole is combined with Quinapril.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Epirizole.Approved
RamiprilThe risk or severity of adverse effects can be increased when Epirizole is combined with Ramipril.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Epirizole is combined with Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Epirizole.Approved, Experimental, Investigational
ReviparinEpirizole may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinEpirizole may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Epirizole is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Epirizole is combined with Risedronate.Approved, Investigational
RivaroxabanEpirizole may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Epirizole is combined with Rofecoxib.Approved, Investigational, Withdrawn
RosoxacinEpirizole may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RufloxacinEpirizole may increase the neuroexcitatory activities of Rufloxacin.Experimental
SabarubicinEpirizole may decrease the excretion rate of Sabarubicin which could result in a higher serum level.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Epirizole.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Epirizole.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Epirizole.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Epirizole.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Epirizole.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Epirizole.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Epirizole.Approved, Investigational
SemapimodThe risk or severity of adverse effects can be increased when Epirizole is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Epirizole.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Epirizole is combined with Serrapeptase.Investigational
SisomicinEpirizole may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinEpirizole may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Epirizole.Approved
SotalolEpirizole may decrease the antihypertensive activities of Sotalol.Approved
SP1049CEpirizole may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinEpirizole may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpectinomycinEpirizole may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Epirizole is combined with Spirapril.Approved
SpironolactoneEpirizole may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Epirizole.Investigational
StreptomycinEpirizole may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinEpirizole may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved, Investigational
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Epirizole.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Epirizole.Approved, Investigational
SulodexideEpirizole may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Epirizole.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Epirizole.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Epirizole is combined with Suxibuzone.Experimental
TacrolimusEpirizole may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Epirizole.Approved
TalinololEpirizole may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Epirizole.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Epirizole.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Epirizole.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Epirizole is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Epirizole is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Epirizole.Approved, Investigational
TemafloxacinEpirizole may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Epirizole is combined with Temocapril.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Epirizole is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Epirizole is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Epirizole.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Epirizole is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Epirizole.Approved
TertatololEpirizole may decrease the antihypertensive activities of Tertatolol.Experimental
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Epirizole.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Epirizole is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololEpirizole may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Epirizole is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Epirizole is combined with Tixocortol.Approved, Withdrawn
TobramycinEpirizole may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Epirizole is combined with Tolfenamic Acid.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Epirizole.Approved
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Epirizole.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Epirizole is combined with Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Epirizole.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Epirizole.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Epirizole.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Epirizole is combined with Triamcinolone.Approved, Vet Approved
TriamtereneEpirizole may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Epirizole is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Epirizole.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Epirizole is combined with Triptolide.Investigational
TrovafloxacinEpirizole may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinEpirizole may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Epirizole is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Epirizole.Approved, Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Epirizole is combined with Valdecoxib.Approved, Investigational, Withdrawn
ValrubicinEpirizole may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Epirizole.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Epirizole.Approved
WarfarinEpirizole may increase the anticoagulant activities of Warfarin.Approved
XimelagatranEpirizole may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Epirizole.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Epirizole.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Epirizole is combined with Zofenopril.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Epirizole is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Epirizole.Withdrawn
Zoptarelin doxorubicinEpirizole may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level.Investigational
ZorubicinEpirizole may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food Interactions
Not Available

References

Synthesis Reference

South African Patent Application 67/4936; January 19, 1968; assigned to Daiichi Seiyaku Company Limited, Japan.

General References
Not Available
External Links
KEGG Drug
D01394
PubChem Compound
3242
PubChem Substance
310264952
ChemSpider
3129
ChEBI
31545
ChEMBL
CHEMBL1411693
Drugs.com
Drugs.com Drug Page
Wikipedia
Epirizole

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)90-92South African Patent Application 67/4936; January 19, 1968; assigned to Daiichi Seiyaku Company Limited, Japan.
Predicted Properties
PropertyValueSource
Water Solubility1.13 mg/mLALOGPS
logP1.56ALOGPS
logP1.45ChemAxon
logS-2.3ALOGPS
pKa (Strongest Basic)2.25ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area62.06 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity62.71 m3·mol-1ChemAxon
Polarizability24.79 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-000i-0390000000-9b005e40342ab7df46f0
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00di-3930000000-1626dd87c849d820e5e4

Taxonomy

Description
This compound belongs to the class of organic compounds known as alkyl aryl ethers. These are organic compounds containing the alkyl aryl ether functional group with the generic formula R-O-R' , where R is an alkyl group and R' is an aryl group.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Ethers
Direct Parent
Alkyl aryl ethers
Alternative Parents
Pyrimidines and pyrimidine derivatives / Pyrazoles / Heteroaromatic compounds / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Hydrocarbon derivatives
Substituents
Alkyl aryl ether / Pyrimidine / Heteroaromatic compound / Pyrazole / Azole / Azacycle / Organoheterocyclic compound / Organic nitrogen compound / Organopnictogen compound / Hydrocarbon derivative
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Drug created on June 10, 2014 17:13 / Updated on March 02, 2018 05:32